Table 2 Responses among patients with measurable lesions
From: Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
All (n = 49) | Good (n = 27) | Poor (n = 22) | |
|---|---|---|---|
CR | 0 | 0 | 0 |
PR | 3 | 2 | 1 |
SD | 8 | 5 | 3 |
PD | 36 | 19 | 17 |
NE | 2 | 1 | 1 |
RR (%) | 6% | 8% | 5% |
DCR (%) | 23% | 27% | 19% |